{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:03:09Z","timestamp":1788393789328,"version":"build-2803163510"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ejca.2026.116602","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:58:36Z","timestamp":1771952316000},"page":"116602","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Is pathological complete response a surrogate for overall survival in neoadjuvant clinical trials for gastroesophageal adenocarcinoma?"],"prefix":"10.1016","volume":"237","author":[{"given":"Lu\u00eds Felipe","family":"Leite","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0889-7425","authenticated-orcid":false,"given":"Mariana Macambira","family":"Noronha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Menezes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas Diniz da","family":"Concei\u00e7\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz F.","family":"Costa de Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anelise Poluboiarinov","family":"Cappellaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Belotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0053-7951","authenticated-orcid":false,"given":"Renata D.\u2019Alpino","family":"Peixoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thais","family":"Baccili Cury Megid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejca.2026.116602_bib1","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_100039","article-title":"Common sense oncology: equity, value, and outcomes that matter","volume":"44","author":"Wilson","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.ejca.2026.116602_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102283","article-title":"A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials","volume":"65","author":"Ciani","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"17","key":"10.1016\/j.ejca.2026.116602_bib3","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1001\/jama.2024.2396","article-title":"Clinical benefit and regulatory outcomes of cancer drugs receiving accelerated approval","volume":"331","author":"Liu","year":"2024","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ejca.2026.116602_bib4","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_100039","article-title":"Common sense oncology: equity, value, and outcomes that matter","volume":"44","author":"Wilson","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"10.1016\/j.ejca.2026.116602_bib5","first-page":"49","article-title":"The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostat Oxf Engl","volume":"1","author":"Buyse","year":"2000"},{"key":"10.1016\/j.ejca.2026.116602_bib6","first-page":"8","article-title":"Surrogate end-points for overall survival in 22 neoadjuvant trials of gastro-oesophageal cancers","volume":"76","author":"Petrelli","year":"2017","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"5","key":"10.1016\/j.ejca.2026.116602_bib7","doi-asserted-by":"crossref","first-page":"169","DOI":"10.6004\/jnccn.2025.0022","article-title":"Gastric cancer, version 2.2025, NCCN clinical practice guidelines in oncology","volume":"23","author":"Ajani","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ejca.2026.116602_bib8","unstructured":"NCCN [Internet]. [cited 2025 Nov 30]. Guidelines Detail. Available from: \u3008https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1433\u3009."},{"issue":"10","key":"10.1016\/j.ejca.2026.116602_bib9","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.annonc.2022.07.003","article-title":"Oesophageal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Obermannov\u00e1","year":"2022","journal-title":"Ann Oncol J Eur Soc Med Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2026.116602_bib10","doi-asserted-by":"crossref","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","article-title":"Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Ajani","year":"2022","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"issue":"4","key":"10.1016\/j.ejca.2026.116602_bib11","doi-asserted-by":"crossref","first-page":"393","DOI":"10.6004\/jnccn.2023.0019","article-title":"Esophageal and esophagogastric junction cancers, version 2.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Ajani","year":"2023","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"issue":"1","key":"10.1016\/j.ejca.2026.116602_bib12","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkz002","article-title":"A systematic review and recommendation for reporting of surrogate endpoint evaluation using meta-analyses","volume":"3","author":"Xie","year":"2019","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.ejca.2026.116602_bib13","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ejca.2026.116602_bib14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Med Res Method"},{"issue":"1","key":"10.1016\/j.ejca.2026.116602_bib15","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1541-0420.2011.01646.x","article-title":"Predicting treatment effect from surrogate endpoints and historical trials: an extrapolation involving probabilities of a binary outcome or survival to a specific time","volume":"68","author":"Baker","year":"2012","journal-title":"Biometrics"},{"issue":"5","key":"10.1016\/j.ejca.2026.116602_bib16","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/jnci\/djs527","article-title":"Surrogate endpoint analysis: an exercise in extrapolation","volume":"105","author":"Baker","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2026.116602_bib17","unstructured":"Elst W.V.D., Stijven F., Ong F., Witte D.D., Deliorman G., Meyvisch P., et al. Surrogate: Evaluation of Surrogate Endpoints in Clinical Trials [Internet]. 2025 [cited 2025 Aug 6]. Available from: \u3008https:\/\/cran.r-project.org\/web\/packages\/Surrogate\/index.html\u3009."},{"issue":"3","key":"10.1016\/j.ejca.2026.116602_bib18","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/pst.207","article-title":"Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation","volume":"5","author":"Burzykowski","year":"2006","journal-title":"Pharm Stat"},{"issue":"11","key":"10.1016\/j.ejca.2026.116602_bib19","article-title":"Long-term efficacy of neoadjuvant concurrent chemoradiotherapy for potentially resectable advanced siewert type II and III adenocarcinomas of the esophagogastric junction","volume":"11","author":"Tian","year":"2021","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2026.116602_bib20","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1200\/JCO.23.00975","article-title":"Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, phase II\/III DANTE\/IKF-s633 trial","volume":"42","author":"Lorenzen","year":"2024","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2026.116602_bib21","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.annonc.2019.10.019","volume":"31","author":"Barbour","year":"2020","journal-title":"Ann Oncol J Eur Soc Med Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2026.116602_bib22","first-page":"354","article-title":"Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial","volume":"47","author":"Burmeister","year":"2011","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"5","key":"10.1016\/j.ejca.2026.116602_bib23","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/ags3.12352","article-title":"Primary results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin\/S-1 and docetaxel\/cisplatin\/S-1 as neoadjuvant chemotherapy for advanced gastric cancer","volume":"4","author":"Hayashi","year":"2020","journal-title":"Ann Gastroenterol Surg"},{"issue":"32","key":"10.1016\/j.ejca.2026.116602_bib24","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1200\/JCO.22.00380","article-title":"FLOT Versus FLOT\/trastuzumab\/pertuzumab perioperative therapy of human epidermal growth factor receptor 2-positive resectable esophagogastric adenocarcinoma: a randomized phase II trial of the AIO EGA study group","volume":"40","author":"Hofheinz","year":"2022","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2026.116602_bib25","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa2409408","article-title":"Perioperative chemotherapy or preoperative chemoradiotherapy in esophageal cancer","volume":"392","author":"Hoeppner","year":"2025","journal-title":"N Engl J Med"},{"issue":"35","key":"10.1016\/j.ejca.2026.116602_bib26","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1200\/JCO.2009.26.6114","article-title":"Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954","volume":"28","author":"Schuhmacher","year":"2010","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2026.116602_bib27","first-page":"492","article-title":"Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial","volume":"24","author":"Iwasaki","year":"2021","journal-title":"Gastric Cancer J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc"},{"issue":"26","key":"10.1016\/j.ejca.2026.116602_bib28","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1200\/JCO.20.02914","article-title":"PRODIGY: a phase III study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer","volume":"39","author":"Kang","year":"2021","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2026.116602_bib29","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ijrobp.2015.12.009","volume":"94","author":"Kleinberg","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"10.1016\/j.ejca.2026.116602_bib30","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa010187","article-title":"Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction","volume":"345","author":"Macdonald","year":"2001","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ejca.2026.116602_bib31","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.3390\/cancers12102790","article-title":"Preoperative or perioperative docetaxel, oxaliplatin, and capecitabine (GASTRODOC Regimen) in patients with locally-advanced resectable gastric cancer: a randomized phase-II trial","volume":"12","author":"Monti","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2026.116602_bib32","first-page":"153","article-title":"Oxaliplatin\/capecitabine or carboplatin\/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): long-term results of a randomised controlled trial","volume":"153","author":"Mukherjee","year":"2021","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"11","key":"10.1016\/j.ejca.2026.116602_bib33","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S2468-1253(23)00243-1","article-title":"Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial","volume":"8","author":"Reynolds","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.ejca.2026.116602_bib34","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S1470-2045(21)00718-X","article-title":"Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology\/RTOG 1010): a multicentre, randomised, phase 3 trial","volume":"23","author":"Safran","year":"2022","journal-title":"Lancet Oncol"},{"issue":"35","key":"10.1016\/j.ejca.2026.116602_bib35","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1200\/JCO.2009.26.6114","article-title":"Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954","volume":"28","author":"Schuhmacher","year":"2010","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2026.116602_bib36","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","article-title":"Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study","volume":"25","author":"Shitara","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116602_bib37","first-page":"183","article-title":"Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): Long-term results of a controlled randomised trial","volume":"81","author":"Stahl","year":"2017","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"2","key":"10.1016\/j.ejca.2026.116602_bib38","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.annonc.2022.10.508","article-title":"Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial","volume":"34","author":"Tang","year":"2023","journal-title":"Ann Oncol J Eur Soc Med Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116602_bib39","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13045-024-01536-7","article-title":"Perioperative versus adjuvant S-1 plus oxaliplatin chemotherapy for stage II\/III resectable gastric cancer (RESONANCE): a randomized, open-label, phase 3 trial","volume":"17","author":"Wang","year":"2024","journal-title":"J Hematol OncolJ Hematol Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2026.116602_bib40","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1159\/000444457","article-title":"Feasibility and safety of transhiatal approach and D2 total gastrectomy after neoadjuvant chemotherapy for adenocarcinoma of the esophago-gastric junction: a subset analysis of the COMPASS trial","volume":"33","author":"Yoshikawa","year":"2016","journal-title":"Dig Surg"},{"key":"10.1016\/j.ejca.2026.116602_bib41","first-page":"214","article-title":"Induction versus no induction chemotherapy before neoadjuvant chemoradiotherapy and surgery in oesophageal adenocarcinoma: a multicentre randomised phase II trial (NCCTG N0849 [Alliance])","volume":"150","author":"Yoon","year":"2021","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"2","key":"10.1016\/j.ejca.2026.116602_bib42","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.0426","article-title":"Effect of S-1 plus oxaliplatin compared with fluorouracil, leucovorin plus oxaliplatin as perioperative chemotherapy for locally advanced, resectable gastric cancer: a randomized clinical trial","volume":"5","author":"Yu","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"19","key":"10.1016\/j.ejca.2026.116602_bib43","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1056\/NEJMoa2405195","article-title":"Preoperative chemoradiotherapy for resectable gastric cancer","volume":"391","author":"Leong","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejca.2026.116602_bib44","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1200\/JCO.2008.17.0506","article-title":"Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction","volume":"27","author":"Stahl","year":"2009","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116602_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.756440","article-title":"Long-term efficacy of neoadjuvant concurrent chemoradiotherapy for potentially resectable advanced siewert type II and III adenocarcinomas of the esophagogastric junction","volume":"11","author":"Tian","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2026.116602_bib46","first-page":"S1738","volume":"36","author":"Tabernero","year":"2025","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2026.116602_bib47","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2503701","article-title":"Perioperative durvalumab in gastric and gastroesophageal junction cancer","volume":"393","author":"Janjigian","year":"2025","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2026.116602_bib48","first-page":"93","article-title":"The eighth edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"10.1016\/j.ejca.2026.116602_bib49","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1002\/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C","article-title":"Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations","volume":"73","author":"Mandard","year":"1994","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2026.116602_bib50","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/cncr.11660","article-title":"Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy","volume":"98","author":"Becker","year":"2003","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2026.116602_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10120-022-01331-8","article-title":"Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition)","volume":"26","author":"Japanese Gastric Cancer Association","year":"2023","journal-title":"Gastric Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2026.116602_bib52","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7076","article-title":"Pathologic complete response in patients with esophageal cancer receiving neoadjuvant chemotherapy or chemoradiation: a systematic review and meta-analysis","volume":"13","author":"Gaber","year":"2024","journal-title":"Cancer Med"},{"issue":"6","key":"10.1016\/j.ejca.2026.116602_bib53","doi-asserted-by":"crossref","DOI":"10.1093\/bjs\/znaf131","article-title":"Evaluation of pathological complete response as a surrogate endpoint for overall survival in resectable oesophageal cancer: integrated analysis of individual patient data from phase III trials","volume":"112","author":"Okui","year":"2025","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejca.2026.116602_bib54","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2017.01.032","article-title":"Surrogate end-points for overall survival in 22 neoadjuvant trials of gastro-oesophageal cancers","volume":"76","author":"Petrelli","year":"2017","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2026.116602_bib55","article-title":"Disease-free survival as a surrogate for overall survival in early-stage pancreatic cancer trials: a correlation meta-analysis","volume":"4","author":"Leite","year":"2025","journal-title":"BMJ Oncol"},{"issue":"10184","key":"10.1016\/j.ejca.2026.116602_bib56","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ejca.2026.116602_bib57","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","article-title":"Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study","volume":"25","author":"Shitara","year":"2024","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116602_bib58","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/ijc.34495","article-title":"Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II\/III trial of the German AIO and Italian GOIM","volume":"153","author":"Goetze","year":"2023","journal-title":"Int J Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2026.116602_bib59","first-page":"1108","article-title":"Evaluation of major pathologic response and pathologic complete response as surrogate end points for survival in randomized controlled trials of neoadjuvant immune checkpoint blockade in resectable in NSCLC","volume":"19","author":"Hines","year":"2024","journal-title":"J Thorac Oncol Publ Int Assoc Study Lung Cancer"},{"key":"10.1016\/j.ejca.2026.116602_bib60","article-title":"Progression-free survival as a surrogate for overall survival in gastro-esophageal cancer trials with immunotherapy: a meta-analysis","volume":"232","author":"Leone","year":"2025","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"2","key":"10.1016\/j.ejca.2026.116602_bib61","article-title":"Is pathological response an adequate surrogate marker for survival in neoadjuvant therapy with immune checkpoint inhibitors?","volume":"10","author":"Sugiyama","year":"2025","journal-title":"ESMO Open [Internet]"},{"issue":"7","key":"10.1016\/j.ejca.2026.116602_bib62","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.annonc.2025.03.019","article-title":"Circulating tumor DNA clearance as a predictive biomarker of pathologic complete response in patients with solid tumors treated with neoadjuvant immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"36","author":"Valenza","year":"2025","journal-title":"Ann Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926003825?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926003825?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T13:28:19Z","timestamp":1773235699000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926003825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":62,"alternative-id":["S0959804926003825"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116602","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is pathological complete response a surrogate for overall survival in neoadjuvant clinical trials for gastroesophageal adenocarcinoma?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116602","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116602"}}